2020
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
Ang Y, Ho G, Soo R, Sundar R, Tan S, Yong W, Ow S, Lim J, Chong W, Soe P, Tai B, Wang L, Goh B, Lee S. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer 2020, 20: 1118. PMID: 33203399, PMCID: PMC7672922, DOI: 10.1186/s12885-020-07616-4.Peer-Reviewed Original ResearchConceptsProgression-free-survivalAdvanced solid tumorsBreast cancer patientsSolid tumorsCancer patientsMedian progression-free-survivalRandomized phase II trialMetastatic breast cancer patientsClinical-benefit rateProphylactic G-CSFNon-haematological toxicityPrimary tumor siteAdministration of sunitinibPhase II trialAdvanced solid cancersMedian OSHaematological toxicityDoxorubicin-cyclophosphamideTrial registrationThe studyII trialNeutrophil nadirPrimary endpointSecondary endpointsG-CSFIntermittent administration
2011
Chapter 41 Parathyroid Hormone, Parathyroid Hormone-Related Protein, and Calcitonin
Holt E, Wysolmerski J. Chapter 41 Parathyroid Hormone, Parathyroid Hormone-Related Protein, and Calcitonin. 2011, 725-745. DOI: 10.1016/b978-0-12-381978-9.10041-1.Peer-Reviewed Original ResearchParathyroid hormoneParathyroid hormone-related proteinMedullary thyroid cancerSerum tumor markersSigns of recurrenceEffect of calcitoninTreatment of osteoporosisMedullary thyroid carcinomaHormone-related proteinTreatment of boneIntermittent administrationCalcium disordersThyroid cancerSmooth muscleThyroid carcinomaAnabolic responseTumor markersUseful agentBaseline levelsPTH analogsCardiovascular systemCalcitoninGrowth factorMammary glandLongitudinal monitoring
2009
Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265–102)
Hong D, LoRusso P, Kurzrock R, Maroun C, Mehran M, Drouin M, Martell R, Wheler J. Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265–102). Journal Of Clinical Oncology 2009, 27: e14516-e14516. DOI: 10.1200/jco.2009.27.15_suppl.e14516.Peer-Reviewed Original ResearchDose levelsSolid tumorsGrade 3 nonhematologic toxicityPhase IDrug-related AEsGrade 4 neutropeniaGrade 4 thrombocytopeniaAdvanced solid tumorsDrug-related toxicityTreatment of patientsDose-dependent increaseVariety of cancersEfficacious exposureNonhematologic toxicitySustained hypertensionAdvanced malignanciesEscalation studyFirst doseIntermittent administrationDisease progressionAvailable small moleculesPD markersXenograft modelPatientsDay 1
2006
Effect of daily parathyroid hormone (1–34) on lumbar fusion in a rat model
Lawrence JP, Ennis F, White AP, Magit D, Polzhofer G, Drespe I, Troiano NW, Grauer JN. Effect of daily parathyroid hormone (1–34) on lumbar fusion in a rat model. The Spine Journal 2006, 6: 385-390. PMID: 16825043, DOI: 10.1016/j.spinee.2005.10.010.Peer-Reviewed Original ResearchConceptsSerum osteocalcin levelsParathyroid hormoneOsteocalcin levelsFusion rateDaily injectionsManual palpationLumbar fusionRat modelIntertransverse process spinal fusionDaily parathyroid hormoneSpinal fusion outcomesPosterolateral lumbar fusionIliac crest autograftSprague-Dawley ratsPreclinical animal studiesGreater fusion rateGreat clinical valuePlacebo groupIntermittent administrationSerum osteocalcinCrest autograftAnabolic effectsSpinal fusionInjectable agentsClinical value
2000
Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity
Jentsch J, Roth R, Taylor J. Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity. Biological Psychiatry 2000, 48: 415-424. PMID: 10978725, DOI: 10.1016/s0006-3223(00)00926-4.Peer-Reviewed Original ResearchConceptsPhencyclidine administrationObject retrieval detour taskFrontal cortical dysfunctionFrontal cortex ablationSubchronic phencyclidine administrationPerformance of trialsDrugs of abusePhencyclidine exposureSubchronic administrationIntermittent administrationCortical dysfunctionDrug withdrawalChronic consumptionDopaminergic dysfunctionBehavioral deficitsPsychotomimetic drugsCorticostriatal functionInhibitory response controlCognitive impairmentImpaired acquisitionNonhuman primatesAdministrationPhencyclidineDysfunctionInhibitory control
1996
Boning Up on Estrogen: New Options, New Concerns
Insogna K, Concato J, Henrich J. Boning Up on Estrogen: New Options, New Concerns. JAMA 1996, 276: 1430-1432. DOI: 10.1001/jama.1996.03540170074037.Peer-Reviewed Original ResearchHormone replacement therapyPostmenopausal osteoporosisOral hormone replacement therapyRegular uterine bleedingInitiation of treatmentLong-term adherenceAlternative regimenEstrogen replacementPostmenopausal womenUterine bleedingProgestational agentsIntermittent administrationBone lossReplacement therapyOnly drugBone breakdownFracture ratesEstrogenWomenOsteoporosisDaily useNew optionsRecent studiesTreatmentBleeding
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply